Immunogenic Peptides for the Treatment of Prostate and Breast Cancer
Description of Invention:
This invention relates to antigenic sequences of the T cell receptor gamma alternate reading frame protein (TARP). TARP is expressed in breast cancer cells and prostate cancer cells. The patent application discloses immunogenic TARP polypeptides that generate an immune response to breast or prostate cancer cells that express TARP. These include sequences modified to make them more immunogenic. The application also discloses specific TARP nucleic acid sequences and host cells transfected with these nucleic acids. This invention may be useful as a therapeutic to treat breast or prostate cancer.
Inventors:
Jay Berzofsky (NCI) Sang-kon Oh (NCI) and Ira Pastan (NCI)
Patent Status:
DHHS Reference No. E-116-2003/0 --
U.S. Provisional Application No. 60/476,467 filed 05 Jun 2003
PCT Application No. PCT/US04/17574 filed 02 Jun 2004, which published as WO 2005/000889 on 06 Jan 2005
U.S. Patent Application No. 10/559,329 filed 02 Dec 2005
Portfolios: Cancer
Cancer -Therapeutics-Immunoconjugates Cancer -Therapeutics-Gene Therapy Cancer -Therapeutics-Vaccines Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
